Related Experiment Video
Updated: Apr 11, 2026
Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
Hepatic arterial infusion plus systemic chemotherapy as third-line or later treatment in colorectal liver metastases
1Department of Oncology, The Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou, China.
Insights
Hepatic arterial infusion chemotherapy (HAI) combined with systemic chemotherapy (SCT) significantly improved survival and progression-free survival in patients with advanced colorectal liver metastases (CLMs) refractory to standard treatment.
Area of Science:
- Oncology
- Gastroenterology
- Chemotherapy
Background:
- Colorectal liver metastases (CLMs) present a significant challenge in palliative care.
- Standard systemic chemotherapy (SCT) may fail in advanced CLM cases.
Purpose of the Study:
- To evaluate the benefit of hepatic arterial infusion chemotherapy (HAI) combined with SCT for patients with CLMs in a palliative setting.
- To compare outcomes of HAI + SCT versus SCT alone in refractory CLM.
Main Methods:
- Retrospective single-center study of 43 patients with CLM after SCT failure.
- Group A: 20 patients received HAI + SCT.
- Group B: 23 historical controls received SCT +/- targeted agents.
Main Results:
- HAI + SCT significantly prolonged overall survival (19.8 vs. 9.0 months) and hepatic progression-free survival (8.1 vs. 4.7 months) compared to SCT alone.
- Response rates (25% vs. 0%) and progression-free survival (5.7 vs. 3.0 months) were also improved with HAI + SCT.
- Three patients (15%) achieved conversion to potentially curative surgery.
Conclusions:
- HAI combined with SCT improves overall survival in advanced CLM refractory to intravenous chemotherapy.
- This combination therapy offers a viable palliative option for select CLM patients.
Backgrounds:
The present study aimed to evaluate benefit of hepatic arterial infusion chemotherapy (HAI) combined with systemic chemotherapy (SCT) for patients with colorectal liver metastases (CLMs) in a palliative setting.
Methods:
This was a retrospective single-center study including 43 consecutive patients with CLM after failure of standard SCT. Among them, 20 (47 %) patients underwent HAI combined with SCT (Group A) and 23 historical control patients who had received SCT with or without targeted agent treatment (Group B).
Results:
The two groups had similar characteristics. Compared with SCT alone, HAI combined with SCT prolonged survival (median 19.8 vs. 9.0 months; P = 0.045). Median hepatic progression-free survival was significantly longer for HAI combined with SCT vs. SCT alone (median 8.1 vs. 4.7 months; P = 0.027), as were response rates (25 and 0 %; P = 0.038) and progression-free survival (median 5.7 vs. 3.0 months; P = 0.02). Three patients (15 %) achieved conversion to potentially curative surgery. Grade 3/4 toxicities for Group A and Group B were neutropenia (5 and 8.7 %, respectively), anemia (5 and 0 %, respectively), and hyperbilirubinemia (0 and 4.3 %, respectively). Other complications were mostly grade 1 or 2.
Conclusions:
HAI combined with SCT treatment can improve overall survival compared with SCT alone in highly advanced CLM refractory to intravenous chemotherapy.
More Related Videos
Related Concept Videos
01:21Hepatic Portal System
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers